Shuchi Nahar's Weekend Blog!

Laurus Labs - Result Update Q4FY21 & Full Year FY21 Twitter Handle: @shuchi_nahar Laurus Labs Limited on 30th April 2021 announced its Q4FY21 and full-year results.  Laurus Lab performed extremely well consecutive in the 4th Quarter of FY21. The company did a robust growth in all three segments. Having a healthy order book for FY 22. Consolidated revenue for the quarter increased by 70% driven by growth in all the divisions. The company has been able to sustain its EBITDA margins, and profitability has also improved to Rs. 297 Crs. for the quarter. Generic API division showcased a robust growth of 61% YoY. Anti Viral segment recorded a robust growth of 70% YoY. Revenue Showcased a healthy growth of 102% YoY. The growth was led by higher LMIC Market volumes and increased volumes from North America and EU Commenced marketing of in-licensed products in the USA to leverage front-end capabilities. Custom Synthesis division recorded a strong growth of 35% YoY. Capacity Expansion – To

Neogen Chemical Ltd - Company Overview & Indian Chemical Industry S ynopsis T witter Handle: @shuchi_nahar Company Overview India’s one of the largest manufacturers of Bromine-based compounds, Inorganic Lithium Salts, which mainly find applications in Pharmaceutical, Agrochemical, Specialty Polymer, Heating, Ventilation and Air Conditioning (HVAC) and Flavors and Fragrance Chemicals. Operating since 1991 with strong portfolio of Organic and Inorganic products.  Customers across multiple industries including Pharma, Engineering, and Agrochem Key export geographies include the USA, Europe, Japan and Middle East Growing contribution from Custom Synthesis and Contract Manufacturing Executing Brownfield manufacturing capacity expansion Promoters are pioneering technocrats with substantial domain expertise cumulative experience of more than six decades Developed strong R&D capabilities with dedicated in-house team. Source: Neogen Chemical AnnualReport & Investor Presentation Comp

The Stronger Conviction for CDMO's - Bright Future Ahead Twitter Handle: @shuchi_nahar 1) Laurus Labs –The Complete Turnaround Story Laurus Labs is a leading R&D driven pharmaceuticals company established in 2005 with its headquarters in Hyderabad. It is among the leaders in the manufacturing of Active Pharmaceutical Ingredients (APIs) for Antiretroviral (ARV) and Hepatitis C (Hep-C) formulations. Other major API segments include therapeutic areas such as Oncology, Cardiovascular, and Anti-Diabetes. From a one-product company in 2010 to an Active Pharmaceutical Ingredients (APIs) company thereafter, the company has now emerged as one of India’s leading manufacturers of generics APIs for various complex therapies. Revenue Comparison FY19 v/s FY20 Significant Growth in CDMO For Detailed Analysis of the above company - https://myweekendspot.blogspot.com/2020/09/laurus-labs-company-overview.html To continue reading this great compilation of CDMO Companies Click the Link :  https://

Ultimate Guide to CRAMS or CDMO  with various Companies to track Twitter Handle: @shuchi_nahar What are CRAMS? CRAMS is defined as the process of outsourcing research services/ product manufacturing activities to organizations which can provide the service at a low cost. CRAMS basically consists of the following two activities: Contract Research and Contract Manufacturing . CRAMS is mainly used in the Pharmaceutical and Biotechnology sectors that require extensive R&D and large-scale manufacturing facilities. It is expected that the demand for contract research and contract manufacturing is expected to increase in India in the future. Roadmap Ahead Investments in the global pharmaceuticals sector to increase to over $1,400 billion over the next 3 years, driven by a number of new medicines. With healthy R&D spending going forward, the Contract Research and Manufacturing (CRAMS) segment offers growth opportunities to Indian companies. Rising demand for generic formulati

Dishman Carbogen Amcis  - Company Overview Twitter Handle: @shuchi_nahar Company Profile   Incorporated in 1983, Dishman Carbogen  Amcis  Limited (DCAL) started out as a manufacturer of quaternary ammonium and phosphate compounds. Having ventured into the CRAMS space in India, the company soon became one of the fastest growing companies. Today, company is a leading global outsourcing partner for the pharmaceutical industry,  offering  a portfolio of development, scale-up, and manufacturing services.   Company is a fully integrated CRAMS player working with global pharmaceutical innovators. Company has a global presence with development and manufacturing facilities across Europe, India, and China. Company provides end-to-end, integrated, high-value, niche CRAMS  offering , right from process research & development to late-stage clinical and commercial manufacturing facilities along with the supply of Active Pharmaceutical Ingredients (API) to innovator pharmaceutical companies.   De